Jazz Pharmaceuticals (JAZZ) | Stock Overview & Key Data
Jazz Pharmaceuticals Performance Comparison
Stock Range
Today's Range
Low: $121.40
High: $124.04
on August 22, 2025
52 Week Range
Low: $95.49
High: $148.06
on April 9, 2025
on February 26, 2025
All-Time High: $194.73 on July 27, 2015
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$7.3B
EPS
-6.98
P/E Ratio (TTM)
14.39
Forward P/E
5.57
P/B Ratio
1.97
PEG Ratio
-0.03
Div. Yield
N/A
ROE
-10.84%
Beta
0.339
Debt to Equity
146.59
Financial Highlights
Profitability
Gross Margin
88.88%
Operating Margin
20.94%
Profit Margin
-9.91%
Returns and Earnings
Return on Assets (TTM)
5.19%
Return on Equity (TTM)
-10.84%
EBITDA
$1.3B
Net Income (TTM)
$-404.8M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$67.40
Quarterly Revenue Growth (YoY)
2.10%
Quarterly Earnings Growth (YoY)
2.14%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Jazz Pharmaceuticals JAZZ | 7.29B Mid-cap | 4.53% | 5.82% | 14.18% | -9.93% | -0.53% | 8.11% | -21.02% | -7.98% |
| Vertex VRTX | 101.31B Large-cap | 0.59% | -15.96% | -8.96% | -17.97% | -2.62% | -17.90% | 40.27% | 46.36% |
| Regeneron REGN | 63.57B Large-cap | 1.56% | 5.09% | -1.23% | -17.35% | -17.58% | -50.84% | -1.12% | -2.18% |
| BridgeBio Pharma BBIO | 9.38B Mid-cap | -4.36% | 7.23% | 48.86% | 35.39% | 74.04% | 93.92% | 368.32% | 65.87% |
| Madrigal MDGL | 9.07B Mid-cap | 12.12% | 32.32% | 51.70% | 28.73% | 32.16% | 64.07% | 491.89% | 288.86% |
| Halozyme HALO | 8.38B Mid-cap | 6.76% | 24.82% | 33.62% | 22.77% | 49.59% | 14.51% | 78.26% | 152.53% |
Ownership & Short Interest
Insider Ownership
3.12%
Institutional Ownership
105.88%
Shares Short
5M
Short Ratio
8.86
Short % of Shares Outstanding
10.45%
Average 10-Day Volume
689K
Average 90-Day Volume
744K
Jazz Pharmaceuticals Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Jazz Pharmaceuticals would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is JAZZ's 52-week high and low?
- In the last 52 weeks, Jazz Pharmaceuticals reached a high of $148.06 (on February 26, 2025) and a low of $95.49 (on April 9, 2025).
- What is the market cap and P/E ratio for JAZZ?
- Curious about Jazz Pharmaceuticals's size and valuation? Its market capitalization stands at 7.29B. When it comes to valuation, the P/E ratio (trailing twelve months) is 14.39, and the forward P/E (looking ahead) is 5.57.
- Does JAZZ pay dividends? If so, what's the yield?
- As for dividends, Jazz Pharmaceuticals isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Jazz Pharmaceuticals's main competitors or similar companies to consider before investing?
When looking at Jazz Pharmaceuticals, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX101.31B Healthcare Biotechnology -17.90% 40.27% Regeneron
REGN63.57B Healthcare Biotechnology -50.84% -1.12% BridgeBio Pharma
BBIO9.38B Healthcare Biotechnology 93.92% 368.32% Madrigal
MDGL9.07B Healthcare Biotechnology 64.07% 491.89% Halozyme
HALO8.38B Healthcare Biotechnology 14.51% 78.26% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Jazz Pharmaceuticals plc? (e.g., ROE, Debt/Equity)
- To get a sense of Jazz Pharmaceuticals's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -10.84%, the Debt to Equity ratio from the most recent quarter is 146.59, and its Gross Profit Margin stands at 88.88%.
- What is the recent revenue and earnings growth for JAZZ?
- Looking at Jazz Pharmaceuticals's growth, its revenue over the trailing twelve months (TTM) was $4B. Compared to the same quarter last year (YoY), quarterly revenue grew by 2.10%, and quarterly earnings saw a YoY growth of 2.14%.
- How much of JAZZ stock is held by insiders and institutions?
- Wondering who owns Jazz Pharmaceuticals stock? Company insiders (like executives and directors) hold about 3.12% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 105.88%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.